


In the Claims:

Please amend the Claims as shown:

Patent Claims

1. (currently amended) Peptide compounds of the formula I
(SEQ ID NO: 2)



in which:

$X^1, X^2, X^3, X^4, X^5, X^6$ each independently of one another are an amino acid residue, the amino acids independently of one another being selected from a group consisting of Ala, Asn, Asp, Arg, Cys, Gln, Glu, Gly, Phe, His, Ile, Leu, Lys, Met, Nle, homo-Phe, Phg, Pro, Ser, Thr, Trp, Tyr or Val, and the amino acids mentioned possibly also being derivatized,

W^1 is H or Ac,

W^2 is OH, OR, NHR, NR_2 , NH_2 ,

R is alkyl having 1-6 C atoms and


n, m each independently of one another are a number from 0-15.

2. (original) Peptide compounds according to Claim 1, in which X^2 is an amino acid residue which is selected from the group consisting of Thr, Ser, Asp or glycine.
3. (original) Peptide compounds according to Claim 1, in which X^3 is an amino acid residue selected from the group consisting of Asp, Glu, Arg, Lys, His or Tyr.
4. (original) Peptide compounds according to Claim 1, in which X^4 is an amino acid residue selected from the group consisting of Ser, Tyr, Thr, Gly or Val.
5. (currently amended) Peptide compounds according to Claim 1 as in the formula V (SEQ ID NO: 19)



having the meanings indicated in Claim 1.

6. (currently amended) Peptide compound according to Claim 5 as in formula VI (SEQ ID NO: 20)



7. (original) Peptide compounds of the formula I or II according to Claims 1 to 6 and their physiologically acceptable salts as medicaments.
8. (original) Medicament according to Claim 7 as an inhibitor for the control of disorders which are based on an expression and pathological function of $\alpha_v\beta_6$ integrin receptors.
9. (original) Medicament according to Claim 8 for the control of thromboses, cardiac infarct, coronary heart disorders, arteriosclerosis, tumours, osteoporosis, fibrosis, inflammations, infections, psoriasis and for influencing wound healing processes.
10. (original) Pharmaceutical preparation comprising at least one medicament according to one of Claims 7 to 9 and, if appropriate, vehicles and/or excipients and, if appropriate, other active compounds.
11. (original) Use of peptide compounds according to Claims 1 to 6 and/or their physiologically acceptable salts for the production of a medicament for controlling disorders which are based on an expression and pathological function of $\alpha_v\beta_6$ integrin receptors.
12. (original) Use according to Claim 11 for the production of a medicament for controlling thromboses, cardiac infarct, coronary heart disorders, arteriosclerosis, tumours, osteoporosis, fibrosis, inflammations, infections, psoriasis and for influencing wound healing processes.
13. (original) Recombinant DNA comprising a sequence which codes for a peptide section which corresponds to a peptide compound of Claims 1-6.
14. (original) Recombinant virus DNA according to Claim 13.
15. (original) Virus, characterized in that it possesses a coat protein which has a sequence which corresponds to a peptide compound of Claims 1-6.
16. (original) Use of a virus according to Claim 15 for the production of a medicament for controlling disorders which are based on an expression and pathological function of $\alpha_v\beta_6$ integrin receptors.